The overexpression of MEG3 can also increase the DDP-sensitivity of NSCLC cell lines (A549 and H1299) [117] and xenografts [118] by decreasing TP53, CTNNB1, survivin (BIRC5), therefore targeting the WNT/β-catenin signaling pathway [118], and Bcl-xl (BCL2L1) [119]. The gene discussed is MEG3; the disease is non-small cell lung carcinoma.